← The Wire·Consumer·

Deals tracker: iRhythm to acquire VitalConnect

iRhythm is set to acquire VitalConnect, adding a transaction catalyst to the company’s growth story. The available data show strong revenue growth but continuing losses, leaving deal execution and the path to profitability as the key setup for IRTC.

STOCK PHOTO · TIMA MIROSHNICHENKO

The story

iRhythm is set to acquire VitalConnect, according to the Deals Tracker item from Modern Healthcare.

The transaction adds a strategic catalyst to IRTC, which reported FY2025 revenue of $747.1M, up 26.2% YoY. The company also recorded a 70.6% gross margin, but remained unprofitable with a -6.0% net margin and $-1.39 diluted EPS.

That combination creates a clear bull case around broader connected-cardiac-monitoring scale and a bear case around integration, funding, and dilution risk.

The next signals are the definitive transaction terms, financing structure, regulatory or closing conditions, and any guidance for revenue, margins, or cash use after the deal.

Our read · Sat, Aug 8

The VitalConnect acquisition adds strategic upside but leaves deal terms, funding and profitability risk unresolved for IRTC.

Why. The acquisition could expand IRTC’s connected-care platform. The existing financial profile is mixed: FY2025 revenue grew 26.2% YoY to $747.1M with a 70.6% gross margin, while net margin was -6.0% and diluted EPS was $-1.39.

Both cases

The case it holdsThe strongest bull case is that VitalConnect broadens IRTC’s monitoring footprint and supports the company’s 26.2% YoY revenue growth trajectory without damaging its 70.6% gross margin.
The case it breaksThe bear case is stronger on the missing facts: with IRTC still at a -6.0% net margin and $-1.39 diluted EPS, an undisclosed purchase price or financing structure could add execution and dilution risk before synergies are proven.

What could change this view: A costly or equity-funded transaction, integration problems, or no improvement in the company’s losses would undermine the strategic case.

iRhythm Holdings stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

modernhealthcare.comoriginalSat, Aug 8 · 5:59 AM ETDeals tracker: iRhythm to acquire VitalConnect

Keep reading

Latest on the Wire

Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by modernhealthcare.com, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →